NCT06363383View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

July 4, 2025

Study Completion Date

July 4, 2025

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

MB-001

Oral, delayed release formulation of a biologic drug

Trial Locations (1)

5000

CMAX, Adelaide

Sponsors

Lead Sponsor

Mage Biologics

Collaborators (1)

Alimentiv Inc.
All Listed Sponsors
collaborator

Alimentiv Inc.

OTHER

lead

Mage Biologics

INDUSTRY

NCT06363383 - A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants | Biotech Hunter | Biotech Hunter